Clinical Trial Update: Pristinamycin in the Treatment of MSSA Bone and Joint Infection

View source ↗

Summary

Clinical trial evaluating pristinamycin for methicillin-susceptible Staphylococcus aureus bone and joint infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis
• Septic Arthritis

Drugs mentioned

• Pristinamycin (pristinamycin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection, Bone and Joint Infection | Status: COMPLETED